Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Wajs, E.
54  Ergebnisse:
Personensuche X
?
1

P.034 Factor analysis of the MADRS over the course of treat..:

Borentain, S. ; Gogate, J. ; Turkoz, I....
European Neuropsychopharmacology.  29 (2019)  - p. S44-S45 , 2019
Link: https://doi.org/10.1016/..
 
?
2

P.033 Managing esketamine treatment frequency toward succes..:

Nijs, M. ; Wajs, E. ; Aluisio, L....
European Neuropsychopharmacology.  29 (2019)  - p. S43-S44 , 2019
Link: https://doi.org/10.1016/..
 
?
3

P.006 Cardiac safety of esketamine nasal spray in treatment..:

Doherty, T. ; Wajs, E. ; Funck-Brentano, C....
European Neuropsychopharmacology.  29 (2019)  - p. S23-S24 , 2019
Link: https://doi.org/10.1016/..
 
?
4

Long-term safety of esketamine nasal spray plus oral antide..:

Wajs, E. ; Leah, A. ; Morrison, R....
European Neuropsychopharmacology.  29 (2019)  - p. S44-S45 , 2019
Link: https://doi.org/10.1016/..
 
?
5

P.327 Withdrawal symptom assessment in an esketamine safety..:

Aluisio, L. ; Wajs, E. ; DiBernardo, A....
European Neuropsychopharmacology.  29 (2019)  - p. S233-S234 , 2019
Link: https://doi.org/10.1016/..
 
?
6

P.038 Effect of esketamine nasal spray on cognition in pati..:

Morrison, R. ; Singh, J. ; Daly, E....
European Neuropsychopharmacology.  29 (2019)  - p. S47-S48 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Efficacy and safety of canagliflozin over 52 weeks in patie..:

Yale, J.‐F. ; Bakris, G. ; Cariou, B....
Diabetes, Obesity and Metabolism.  16 (2014)  10 - p. 1016-1027 , 2014
Link: https://doi.org/10.1111/..
 
?
8

P304 Efficacité et tolérance de la canagliflozine sur une p..:

Nieto, J. ; Yale, J. ; Bakris, G....
Diabetes & Metabolism.  40 (2014)  - p. A99 , 2014
Link: https://doi.org/10.1016/..
 
?
9

Improvement of the Performance Parameters of Precision Fric..:

Svirid, M. N. ; Wajs, E. ; Primak, L. B...
Powder Metallurgy and Metal Ceramics.  52 (2013)  7-8 - p. 417-423 , 2013
Link: https://doi.org/10.1007/..
 
?
10

Efficacy and safety of canagliflozin in subjects with type ..:

Yale, J.‐F. ; Bakris, G. ; Cariou, B....
Diabetes, Obesity and Metabolism.  15 (2013)  5 - p. 463-473 , 2013
Link: https://doi.org/10.1111/..
 
?
11

A placebo‐controlled trial of the 5‐HT1A agonist R‐137696 o..:

Tack, J. ; Van Den Elzen, B. ; Tytgat, G....
Neurogastroenterology & Motility.  21 (2009)  6 - p. 619 , 2009
Link: https://doi.org/10.1111/..
 
?
12

The WC-Co electrospark alloying coatings modified by laser ..:

Radek, N. ; Wajs, E. ; Luchka, M.
Powder Metallurgy and Metal Ceramics.  47 (2008)  3-4 - p. 197-201 , 2008
Link: https://doi.org/10.1007/..
 
?
13

Reproducibility and symptomatic predictors of a slow nutrie..:

Kindt, S. ; Coulie, B. ; Wajs, E...
Neurogastroenterology & Motility.  20 (2008)  4 - p. 320-329 , 2008
Link: https://doi.org/10.1111/..
 
?
14

The 5‐HT4 antagonist R216073 does not affect gastric motor ..:

VAN LELYVELD, N. ; TER LINDE, J. ; BARON, A....
Alimentary Pharmacology & Therapeutics.  24 (2006)  4 - p. 669-677 , 2006
Link: https://doi.org/10.1111/..
 
?
15

The influence of the novel 5‐HT1A agonist R137696 on the pr..:

Boeckxstaens, G. E. ; Tytgat, G. N. ; Wajs, E....
Neurogastroenterology & Motility.  18 (2006)  10 - p. 919-926 , 2006
Link: https://doi.org/10.1111/..
 
1-15